Jalra 50mg Tablet contains Vildagliptin 50mg, an oral antihyperglycemic agent used in the management of type 2 diabetes mellitus. Vildagliptin belongs to the class of dipeptidyl peptidase-4 (DPP-4) inhibitors, which work by enhancing the incretin system. This mechanism increases insulin secretion and decreases glucagon release in a glucose-dependent manner, thereby improving glycemic control without causing significant hypoglycemia. Jalra 50mg is indicated as monotherapy in patients inadequately controlled by diet and exercise alone, or as combination therapy with other antidiabetic agents such as metformin, sulfonylureas, or insulin. It is particularly beneficial for patients who require improved postprandial and fasting blood glucose levels. The medication is generally well tolerated; however, common adverse effects may include headache, dizziness, and gastrointestinal disturbances. Caution is advised in patients with renal impairment, and dosage adjustments may be necessary. Jalra 50mg should be used as part of a comprehensive diabetes management plan including diet, exercise, and regular monitoring of blood glucose levels. It is contraindicated in patients with type 1 diabetes or diabetic ketoacidosis. Healthcare professionals should evaluate individual patient factors before initiating therapy.